Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis

BACKGROUND: Osimertinib is the first-line therapeutic option for the T790M-mutant non-small-cell lung cancer and the acquired resistance obstructs its application. It is an urgent challenge to identify the potential mechanisms of osimertinib resistance for uncovering some novel therapeutic approache...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Qing, Wang, Jing, Ren, Yaoyao, Meng, Fanlu, Zeng, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103047/
https://www.ncbi.nlm.nih.gov/pubmed/32256584
http://dx.doi.org/10.1155/2020/6249829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103047/
https://www.ncbi.nlm.nih.gov/pubmed/32256584
http://dx.doi.org/10.1155/2020/6249829

Ejemplares similares